Tin tức & Cập nhật
Xem bài viết Nhi khoa
Xem
Chỉ hiển thị Multimedia

Lebrikizumab–topical corticosteroid combo improves outcomes in moderate-to-severe AD
16 Jan 2023
bởiJairia Dela Cruz
Treatment with lebrikizumab, when combined with low- to mid-potency topical corticosteroid (TCS), helps reduce disease severity in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD), with a safety profile consistent with that reported in previous AD studies, according to the phase III ADhere trial.
16 Jan 2023







